AtriCure, Inc. (NASDAQ:ATRC) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of AtriCure, Inc. (NASDAQ:ATRC) have received an average rating of “Moderate Buy” from the eleven analysts that are currently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating and ten have assigned a buy rating to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $52.4444.

Several research firms have recently issued reports on ATRC. Canaccord Genuity Group increased their price objective on shares of AtriCure from $53.00 to $64.00 and gave the company a “buy” rating in a report on Thursday, October 30th. Weiss Ratings restated a “sell (d-)” rating on shares of AtriCure in a research report on Wednesday, October 8th. JPMorgan Chase & Co. increased their price target on AtriCure from $42.00 to $48.00 and gave the company an “overweight” rating in a research note on Tuesday, December 16th. Finally, Citigroup reissued a “market outperform” rating on shares of AtriCure in a research note on Thursday, October 30th.

Insider Buying and Selling

In other AtriCure news, Director Maggie Yuen sold 3,000 shares of the business’s stock in a transaction dated Friday, November 21st. The shares were sold at an average price of $35.72, for a total value of $107,160.00. Following the sale, the director directly owned 11,371 shares in the company, valued at approximately $406,172.12. The trade was a 20.88% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Justin J. Noznesky sold 5,166 shares of the company’s stock in a transaction dated Wednesday, November 26th. The shares were sold at an average price of $37.29, for a total transaction of $192,640.14. Following the completion of the sale, the insider directly owned 78,798 shares of the company’s stock, valued at $2,938,377.42. The trade was a 6.15% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 18,166 shares of company stock valued at $676,378 over the last three months. Company insiders own 3.50% of the company’s stock.

Institutional Trading of AtriCure

Large investors have recently added to or reduced their stakes in the business. Oberweis Asset Management Inc. acquired a new position in AtriCure in the third quarter worth approximately $5,411,000. Voloridge Investment Management LLC boosted its stake in shares of AtriCure by 1.5% during the 3rd quarter. Voloridge Investment Management LLC now owns 273,749 shares of the medical device company’s stock worth $9,650,000 after acquiring an additional 4,041 shares in the last quarter. Verition Fund Management LLC grew its holdings in shares of AtriCure by 126.8% in the 3rd quarter. Verition Fund Management LLC now owns 17,752 shares of the medical device company’s stock worth $626,000 after acquiring an additional 9,924 shares during the last quarter. Qube Research & Technologies Ltd grew its holdings in shares of AtriCure by 203.6% in the 3rd quarter. Qube Research & Technologies Ltd now owns 94,729 shares of the medical device company’s stock worth $3,339,000 after acquiring an additional 63,531 shares during the last quarter. Finally, Focus Partners Wealth raised its position in shares of AtriCure by 10.1% during the third quarter. Focus Partners Wealth now owns 19,880 shares of the medical device company’s stock worth $691,000 after purchasing an additional 1,824 shares during the period. 99.11% of the stock is currently owned by institutional investors.

AtriCure Price Performance

Shares of NASDAQ ATRC opened at $40.59 on Thursday. The stock has a market cap of $2.02 billion, a P/E ratio of -66.53 and a beta of 1.47. The firm’s 50-day simple moving average is $36.68 and its 200 day simple moving average is $35.07. AtriCure has a fifty-two week low of $28.29 and a fifty-two week high of $43.11. The company has a quick ratio of 2.85, a current ratio of 3.87 and a debt-to-equity ratio of 0.15.

AtriCure (NASDAQ:ATRC) last announced its earnings results on Wednesday, October 29th. The medical device company reported ($0.01) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.10. The firm had revenue of $134.27 million during the quarter, compared to analyst estimates of $131.25 million. AtriCure had a negative net margin of 5.55% and a negative return on equity of 2.54%. AtriCure’s revenue was up 15.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.17) EPS. AtriCure has set its FY 2025 guidance at -0.260–0.230 EPS. Equities analysts expect that AtriCure will post -0.6 EPS for the current year.

About AtriCure

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.